Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease

NEW YORK, NY / ACCESSWIRE / November 30, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company ' s New Drug Application (NDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news